Wnt inhibitory factor-1 functions as a tumor suppressor through modulating Wnt/β-catenin signaling in neuroblastoma

Cancer Letters

Volumn 348, Issue 1-2, 2014, Pages 12-19

  Zhang, Jiao ^a   Zhou, Bin ^a   Liu, Yinghua ^a   Chen, Keling ^a   Bao, Pingqian ^a   Wang, Yi ^a   Wang, Jiaxiang ^b   Zhou, Zongguang ^a   Sun, Xiaofeng ^a,c   Li, Yuan ^a  

^a SICHUAN UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

^c LINKÖPING UNIVERSITY   (Sweden)

Author keywords

Methylation; Neuroblastoma; Wnt inhibitory factor 1 (WIF 1); Wnt catenin signaling

Indexed keywords

BETA CATENIN; GENOMIC DNA; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; WNT INHIBITORY FACTOR 1; WNT PROTEIN;

ARTICLE; CANCER GROWTH; CANCER INHIBITION; CANCER TISSUE; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; EXPOSURE; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; METHYLATION; NEUROBLASTOMA; NEUROBLASTOMA CELL LINE; PLASMID; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION; SK N SH CELL LINE; UPREGULATION; WNT SIGNALING PATHWAY;

METHYLATION; NEUROBLASTOMA; WNT INHIBITORY FACTOR-1 (WIF-1); WNT/Β-CATENIN SIGNALING;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; BETA CATENIN; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN D1; DNA METHYLATION; DNA MODIFICATION METHYLASES; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HEK293 CELLS; HUMANS; NEUROBLASTOMA; PROMOTER REGIONS, GENETIC; REPRESSOR PROTEINS; TIME FACTORS; TRANSFECTION; TUMOR SUPPRESSOR PROTEINS; WNT SIGNALING PATHWAY;

EID: 84900468930     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2014.02.011     Document Type: Article

References (45)

1. Maris J.M. Recent advances in neuroblastoma. N Engl. J. Med. 2010, 362:2202-2211.
2. London W.B., Castleberry R.P., Matthay K.K., Look A.T., Seeger R.C., Shimada H., Thorner P., Brodeur G., Maris J.M., Reynolds C.P., Cohn S.L. Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the Children's Oncology Group. J. Clin. Oncol. 2005, 23:6459-6465.
3. Taipale J., Beachy P.A. The Hedgehog and Wnt signalling pathways in cancer. Nature 2001, 411:349-354.
4. Morin P.J., Sparks A.B., Korinek V., Barker N., Clevers H., Vogelstein B., Kinzler K.W. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science 1997, 275:1787-1790.
5. Weeraratna A.T., Jiang Y., Hostetter G., Rosenblatt K., Duray P., Bittner M., Trent J.M. Wnt5a signaling directly affects cell motility and invasion of metastatic melanoma. Cancer Cell 2002, 1:279-288.
6. Uematsu K., He B., You L., Xu Z., McCormick F., Jablons D.M. Activation of the Wnt pathway in non small cell lung cancer: evidence of dishevelled overexpression. Oncogene 2003, 22. 721872-21.
7. Hallett Robin M., Kondratyev Maria K., Giacomelli Andrew O., Nixon Allison M.L., Girgis-Gabardo Adele, Ilieva Dora, Hassell John A. Small molecule antagonists of the Wnt/Beta-Catenin signaling pathway target breast tumor-initiating cells in a Her2/Neu mouse model of breast cancer. PLoS One 2012, 7:e33976.
8. Rubin J.S., Barshishat-Kupper M., Feroze-Merzouq F., Xi Z.F. Secreted WNT antagonists as tumor suppressors: pro and con. Front Biosci. 2006, 11:2093-2105.
9. Rubin J.S., Bottaro D.P. Loss of secreted frizzled-related protein-1 expression in renal cell carcinoma reveals a critical tumor suppressor function. Clin. Cancer Res. 2007, 13:4660-4663.
10. Clevers H., Nusse R. Wnt/β-catenin signaling and disease. Cell 2012, 149:1192-1205.
11. Zhi F., Gong G., Xu Y., Zhu Y., Hu D., Yang Y., Hu Y. Activated β-catenin forces N2A cell-derived neurons back to tumor-like neuroblasts and positively correlates with a risk for human neuroblastoma. Int. J. Biol. Sci. 2012, 8:289-297.
12. Hsieh J.C., Kodjabachian L., Rebbert M.L., Rattner A., Smallwood P.M., Samos C.H., Nusse R., Dawid I.B., Nathans J. A new secreted protein that binds to Wnt proteins and inhibits their activities. Nature 1999, 398:431-436.
13. Malinauskas T., Aricescu A.R., Lu W., Siebold C., Jones E.Y. Modular mechanism of Wnt signaling inhibition by Wnt Inhibitory Factor 1. Nat. Struct. Mol. Biol. 2011, 18:886-893.
14. He T.C., Sparks A.B., Raqo C., Hermeking H., Zawel L., da Costa L.T., Morin P.J., Vogelstein B., Kinzler K.W. Identification of c-MYC as a target of the APC pathway. Science 1998, 281:1509-1512.
15. Tetsu O., McCormick F. Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 1999, 398:422-426.
16. Kawakami K., Hirata H., Yamamura S., Kikuno N., Saini S., Majid S., Tanaka Y., Kawamoto K., Enokida H., Nakagawa M., Dahiya R. Functional significance of Wnt inhibitory factor-1 gene in kidney cancer. Cancer Res. 2009, 69:8603-8610.
17. Mazieres J., He B., You L., Xu Z., Lee A.Y., Mikami I., Reguart N., Rosell R., McCormick F., Jablons D.M. Wnt inhibitory factor-1 is silenced by promoter hypermethylation in human lung cancer. Cancer Res. 2004, 64:4717-4720.
18. Rubin E.M., Guo Y., Tu K., Xie J., Zi X., Hoanq B.H. Wnt Inhibitory Factor 1 decreases tumorigenesis and metastasis in osteosarcoma. Mol. Cancer Ther. 2010, 9:731-741.
19. Deng Y., Yu B., Cheng Q., Jin J., You H., Ke R., Tang N., Shen Q., Shu H., Yao G., Zhang Z., Qin W. Epigenetic silencing of WIF-1 in hepatocellular carcinomas. J. Cancer Res. Clin. Oncol. 2010, 136:1161-1167.
20. Wu D., Wong P., Li W., Vogel C.F., Matsumura F. Suppression of WIF-1 through promoter hypermethylation causes accelerated proliferation of the aryl hydrocarbon receptor (AHR) overexpressing MCF10AT1 breast cancer cells. Toxicology 2011, 285:97-103.
21. Urakami S., Shiina H., Enokida H., Kawakami T., Tokizane T., Ogishima T., Tanaka Y., Li L.C., Ribeiro-Filho L.A., Terashima M., Kikuno N., Adachi H., Yoneda T., Kishi H., Shigeno K., Konety B.R., Igawa M., Dahiya R. Epigenetic inactivation of Wnt inhibitory factor-1 plays an important role in bladder cancer through aberrant canonical Wnt/beta-catenin signaling pathway. Clin. Cancer Res. 2006, 12:383-391.
22. Kawamoto K., Hirata H., Kikuno N., Tanaka Y., Nakagawa M., Dahiya R. DNA methylation and histone modifications cause silencing of Wnt antagonist gene in human renal cell carcinoma cell lines. Int. J. Cancer 2008, 123:535-542.
23. Schmittgen T.D., Livak K.J. Analyzing real-time PCR data by the comparative C(T) method. Nat. Protoc. 2008, 3:1101-1108.
24. Yu V.C., Hochhaus G., Chang F.H., Richards M.L., Bourne H.R., Sadee W. Differentiation of human neuroblastoma cells: marked potentiation of prostaglandin E-stimulated accumulation of cyclic AMP by retinoic acid. J. Neurochem. 1988, 51:1892-1899.
25. Valentiner U., Valentiner F.U., Schumacher U. Expression of CD44 is associated with a metastatic pattern of human neuroblastoma cells in a SCID mousexenograft model. Tumour Biol. 2008, 29:152-160.
26. Reguart N., He B., Xu Z., You L., Lee A.Y., Mazieres J., Mikami I., Batra S., Rosell R., McCormick F., Jablons D.M. Cloning and characterization of the promoter of human Wnt inhibitory factor-1. Biochem. Biophys. Res. Commun. 2004, 323:229-234.
27. Korinek V., Barker N., Morin P.J., van Wichen D., de Weger R., Kinzler K.W., Vogelstein B., Clevers H. Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC-/- colon carcinoma. Science 1997, 275:1784-1787.
28. Lüchtenborg M., Weijenberg M.P., Roemen G.M., de Bruïne A.P., van den Brandt P.A., Lentjes M.H., Brink M., van Engeland M., Goldbohm R.A., de Goeij A.F. APC mutations in sporadic colorectal carcinomas from The Netherlands Cohort Study. Carcinogenesis 2004, 25:1219-1226.
29. Karim R., Tse G., Putti T., Scolyer R., Lee S. The significance of the Wnt pathway in the pathology of human cancers. Pathology 2004, 36:120-128.
30. Herbst A., Kolligs F.T. Wnt signaling as a therapeutic target for cancer. Methods Mol. Biol. 2007, 361:63-91.
31. Katoh H., Yamashita K., Waraya M., Margalit O., Ooki A., Tamaki H., Sakagami H., Kokubo K., Sidransky D., Watanabe M. Epigenetic silencing of HOPX promotes cancer progression in colorectal cancer. Neoplasia 2012, 14:559-571.
32. Herman J.G., Baylin S.B. Gene silencing in cancer in association with promoter hypermethylation. N Engl. J. Med. 2003, 349:2042-2054.
33. Lin Y.C., You L., Xu Z., He B., Yang C.T., Chen J.K., Mikami I., Clément G., Shi Y., Kuchenbecker K., Okamoto J., Kashani-Sabet M., Jablons D.M. Wnt inhibitory factor-1 gene transfer inhibits melanoma cell growth. Hum. Gene Ther. 2007, 18:379-386.
34. Liu Y.L., Yang H.P., Zhou X.D., Gong L., Tang C.L., Wang H.J. The hypomethylation agent bisdemethoxycurcumin acts on the WIF-1 promoter, inhibits the canonical Wnt pathway and induces apoptosis in human non-small-cell lung cancer. Curr. Cancer Drug Targets 2011, 11:1098-1110.
35. Lee B.B., Lee E.J., Jung E.H., Chun H.K., Chang D.K., Song S.Y., Park J., Kim D.H. Aberrant methylation of APC, MGMT, RASSF2A, and WIF-1 genes in plasma as a biomarker for early detection of colorectal cancer. Clin. Cancer Res. 2009, 15:6185-6191.
36. Batra S., Shi Y., Kuchenbecker K.M., He B., Reguart N., Mikami I., You L., Xu Z., Lin Y.C., Clément G., Jablons D.M. Wnt inhibitory factor-1, a Wnt antagonist, is silenced by promoter hypermethylation in malignant pleural mesothelioma. Biochem. Biophys. Res. Commun. 2006, 342:1228-1232.
37. Kim J., You L., Xu Z., Kuchenbecker K., Raz D., He B., Jablons D. Wnt inhibitory factor inhibits lung cancer cell growth. J. Thorac. Cardiovasc. Surg. 2007, 133:733-737.
38. Lu W., Tinsley H.N., Keeton A., Qu Z., Piazza G.A., Li Y. Suppression of Wnt/beta-catenin signaling inhibits prostate cancer cell proliferation. Eur. J. Pharmacol. 2009, 602:8-14.
39. Schlange T., Matsuda Y., Lienhard S., Huber A., Hynes N.E. Autocrine WNT signaling contributes to breast cancer cell proliferation via the canonical WNT pathway and EGFR transactivation. Breast Cancer Res. 2007, 9:R63.
40. Kaur P., Mani S., Cros M.P., Scoazec J.Y., Chemin I., Hainaut P., Herceg Z. Epigenetic silencing of sFRP1 activates the canonical Wnt pathway and contributes to increased cell growth and proliferation in hepatocellular carcinoma. Tumour Biol. 2012, 33:325-336.
41. Zhang S., Li Y., Wu Y., Shi K., Bing L., Hao J. Wnt/β-catenin signaling pathway upregulates c-Myc expression to promote cell proliferation of P19 teratocarcinoma cells. Anat. Rec. (Hoboken) 2012, 295:2104-2113.
42. Wang C., Tai Y., Lisanti M.P., Liao D.J. C-Myc induction of programmed cell death may contribute to carcinogenesis: a perspective inspired by several concepts of chemical carcinogenesis. Cancer Biol. Ther. 2011, 11:615-626.
43. Tarapore R.S., Siddiqui I.A., Saleem M., Adhami V.M., Spiegelman V.S., Mukhtar H. Specific targeting of Wnt/β-catenin signaling in human melanoma cells by a dietary triterpene lupeol. Carcinogenesis 2010, 31:1844-1853.
44. Georgopoulou N., Hurel C., Politis P.K., Gaitanou M., Matsas R., Thomaidou D. BM88 is a dual function molecule inducing cell cycle exit and neuronal differentiation of neuroblastoma cells via cyclin D1 down-regulation and retinoblastoma protein hypophosphorylation. J. Biol. Chem. 2006, 281:33606-33620.
45. Budhram-Mahadeo V.S., Irshad S., Bowen S., Lee S.A., Samady L., Tonini G.P., Latchman D.S. Proliferation-associated Brn-3b transcription factor can activate cyclin D1 expression in neuroblastoma and breast cancer cells. Oncogene 2008, 27:145-154.